N-terminal propeptide of procollagen type III (PIIINP) and methotrexate
Last edited 02/2021 and last reviewed 02/2021
In patients with psoriasis on methotrexate, measurement of procollagen III N-terminal peptide is advised as an indicator of hepatic fibrosis, although this is usually performed in secondarycare (1,2)
What is procollagen III N-terminal peptide?
- process of liver fibrosis is assumed to be caused by the excess production of extracellular matrix (ECM) in hepatic stellate cells (HSCs) (3,4)
- the increase of ECM deposited fragments in the Disse's space leads to liver injury
- largest component of the ECM is collagen
- in the liver type III collagen mainly occurs
- during the synthesis of type III collagen, the N-terminal propeptide of procollagen type III (PIIINP) is detached from procollagen type III (5)
- so the fibrogenesis results in release of ECM fragments into the blood
- quantity of propeptide of procollagen type III can be a direct indicator of collagen synthesis and its deposition in the extracellular space
- increased amount of propeptide of type III procollagen may indicate the transformation of normal liver tissue into connective tissue (1,2,3,4)
Notes (6):
- PIIINP is not a liver-specific marker
- increased concentrations of PIIINP have also been other conditions associated with abnormal production of collagen
- for example congestive heart failure, hypertension, coronary heart disease and pulmonary fibrosis
Reference:
- Spencer NJ et al. Blood test monitoring of immunomodulatory therapy in inflammatory disease. BMJ 2021; 372: n159 http ://dx .doi.org/ 10.1136/ bmj.n159
- Warren RB, Weatherhead SC, Smith CH, etal. British Association of Dermatologists'guidelinesfor the safe and effective prescribing of methotrexate for skin disease 2016.Br J Dermatol 2016;175:23-44. doi: 10.1111/bjd.14816
- Liu X, Wu H, Byrne M, et al. Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci U S A. 1997;94:1852-6.
- Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-18.
- Cross TJ, Calvaruso V, Maimone S, et al. Prospective comparison of Fibroscan, King’s score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat. 2010;17:546-54.
- Baranova A, Lal P, Birerdinc A, et al. Non-Invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91-6.